Health Care [ 5/12 ] | Life Sciences Tools & Services [ 3/74 ]
NASDAQ | Common Stock
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries.
The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions.
Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research.
The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; and PurePep Symphony and Chorus instruments for peptide synthesis.
Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as renal care, gas flow, environmental and process monitoring, and torque testing in pharmaceutical, laboratory, medical device, manufacturing, industrial, and environmental applications.
This segment's products include continuous monitoring systems, data loggers, and torque testing systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands.
Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 27, 26 | 1.83 Decreased by -18.78% | 1.39 Increased by +31.47% |
| Feb 3, 26 | 1.76 Increased by +122.78% | 1.47 Increased by +19.73% |
| Nov 6, 25 | 2.11 Decreased by -2.31% | 1.56 Increased by +35.26% |
| Aug 5, 25 | 1.88 Decreased by -4.08% | 2.16 Decreased by -12.96% |
| May 28, 25 | 2.25 Decreased by -39.19% | 1.91 Increased by +17.80% |
| Feb 4, 25 | 0.79 Decreased by -69.85% | 1.51 Decreased by -47.68% |
| Nov 7, 24 | 2.16 Increased by +13.09% | 1.38 Increased by +56.52% |
| Aug 5, 24 | 1.96 Increased by +94.06% | 1.55 Increased by +26.45% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 63.72 M Increased by +2.56% | -4.14 M Increased by +41.86% | Decreased by -6.49% Increased by +43.31% |
| Dec 31, 25 | 65.13 M Increased by +3.64% | 3.63 M Increased by +316.59% | Increased by +5.57% Increased by +308.98% |
| Sep 30, 25 | 60.74 M Increased by +5.02% | 2.48 M Decreased by -27.77% | Increased by +4.08% Decreased by -31.22% |
| Jun 30, 25 | 59.54 M Increased by +2.36% | 4.74 M Increased by +39.96% | Increased by +7.96% Increased by +36.74% |
| Mar 31, 25 | 62.13 M Increased by +5.49% | -7.11 M Increased by +97.21% | Decreased by -11.45% Increased by +97.35% |
| Dec 31, 24 | 62.84 M Increased by +17.52% | -1.68 M Decreased by -179.21% | Decreased by -2.67% Decreased by -167.40% |
| Sep 30, 24 | 57.83 M Increased by +8.78% | 3.43 M Increased by +378.70% | Increased by +5.93% Increased by +356.20% |
| Jun 30, 24 | 58.17 M Increased by +14.86% | 3.39 M Increased by +717.12% | Increased by +5.82% Increased by +637.29% |